These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1331 related items for PubMed ID: 23198977

  • 1. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM, Shiff SJ, Quigley EM.
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [Abstract] [Full Text] [Related]

  • 2. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD.
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [Abstract] [Full Text] [Related]

  • 3. Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation.
    Blackshaw LA, Brierley SM.
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):15-9. PubMed ID: 23859756
    [Abstract] [Full Text] [Related]

  • 4. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
    Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM.
    Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
    [Abstract] [Full Text] [Related]

  • 5. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
    Rao SS, Quigley EM, Shiff SJ, Lavins BJ, Kurtz CB, MacDougall JE, Currie MG, Johnston JM.
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
    [Abstract] [Full Text] [Related]

  • 6. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
    Vazquez-Roque MI, Bouras EP.
    Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
    [Abstract] [Full Text] [Related]

  • 7. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
    Videlock EJ, Cheng V, Cremonini F.
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
    [Abstract] [Full Text] [Related]

  • 8. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH, Luthin DR.
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [Abstract] [Full Text] [Related]

  • 9. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
    Rothstein RD, Friedenberg FK.
    Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
    [Abstract] [Full Text] [Related]

  • 10. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
    Vazquez Roque M, Camilleri M.
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):301-10. PubMed ID: 21651347
    [Abstract] [Full Text] [Related]

  • 11. Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
    Layer P, Stanghellini V.
    Aliment Pharmacol Ther; 2014 Feb; 39(4):371-84. PubMed ID: 24433216
    [Abstract] [Full Text] [Related]

  • 12. How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?
    Tack J.
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):21-6. PubMed ID: 23859757
    [Abstract] [Full Text] [Related]

  • 13. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
    Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, Jin H, Jacobson S, Hannig G, Mann E, Cohen MB, MacDougall JE, Lavins BJ, Kurtz CB, Silos-Santiago I, Johnston JM, Currie MG, Blackshaw LA, Brierley SM.
    Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
    [Abstract] [Full Text] [Related]

  • 14. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
    Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, O'Dea C, Baird M, Lembo AJ.
    Gastroenterology; 2010 Dec; 139(6):1877-1886.e2. PubMed ID: 20801122
    [Abstract] [Full Text] [Related]

  • 15. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM.
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [Abstract] [Full Text] [Related]

  • 16. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Kurtz CB, Sharma V, Johnston JM, Currie MG, Zinsmeister AR.
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [Abstract] [Full Text] [Related]

  • 17. The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.
    Lee N, Wald A.
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):651-9. PubMed ID: 21446888
    [Abstract] [Full Text] [Related]

  • 18. Linaclotide for constipation-predominant IBS.
    Drug Ther Bull; 2013 Nov; 51(11):129-32. PubMed ID: 24227771
    [Abstract] [Full Text] [Related]

  • 19. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y, Fang J, Guo X, Dai N, Shen X, Yang Y, Sun J, Bhandari BR, Reasner DS, Cronin JA, Currie MG, Johnston JM, Zeng P, Montreewasuwat N, Chen GZ, Lim S.
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [Abstract] [Full Text] [Related]

  • 20. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
    Fukudo S, Nakajima A, Fujiyama Y, Kosako M, Nakagawa A, Akiho H, Nakashima Y, Johnston JM, Miwa H.
    Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.